Evaluation of Chemotherapy Drug Use in Ovarian Cancer Patients at RSUP Fatmawati for the Period of September 2024.
##plugins.themes.academic_pro.article.sidebar##
##plugins.themes.academic_pro.article.main##
Abstract
Ovarian cancer is a major malignancy in the female reproductive system. Treatment for this cancer can involve surgical
procedures or the use of chemotherapy drugs, either orally or intravenously. This study was conducted to evaluate the use of
chemotherapy drugs in ovarian cancer patients at RSUP Fatmawati. Data collection was carried out through a retrospective
observation by gathering information on drug usage from the patients' medical records, which included data from 31 patients
receiving treatment at RSUP Fatmawati in September 2024. Based on the obtained data, it was found that the most commonly
used chemotherapy drug for cancer patients at RSUP Fatmawati is TAC (Paclitaxel + Carboplatin), accounting for 80.65%.
Additionally, based on the chemotherapy regimens used at RSUP Fatmawati, the recovery percentage from several regimens
ranged from 54.90% to 131.93%.
##plugins.themes.academic_pro.article.details##
References
• Alfia Nursetiani, E. H. (2020). identifikasi persentase kelengkapan resep di salah satu rumah sakit di kota bandung. Farmaka, Volume 18 Nomor 2.
• C. Marth, D. R. (2017). Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Annals of Oncology 28, (Supplement 8): 36–39.
• Choery Novitasari, ,. A. (2020). Perbandingan Angka Ketahanan Hidup Penderita Kanker Ovarium yang Mendapat Terapi Regimen Kemoterapi Paclitaxel-Carboplatin dan
Cyclophosphamide Adiamycin-Cisplatin di RSUP Dr.Sardjito: Studi retrospektif Januari 2014- Desember 2018. Jurnal Kesehatan Reproduksi , Vol 7 No 2.
• Deborah K. Armstrong, R. D.-G. (2021). Ovarian Cancer, Version 2.2020. nccn clinical practice guidelines in oncology, Volume 19 Issue 2.
• Diedra, L. B. (2021). Drug Information Handbook for Oncology. United states: Lexicomp.
• Globacan. (2022). Statistics at Glance (Global Cancer Observatory). International Agency for Research on Cancer .
• Graziele Fonseca de Sousa, S. R. (2014). Carboplatin: molecular mechanisms of action associated with chemoresistance. Brazilian Journal of Pharmaceutical Science, vol.
50 .
• Julie M. Akin, J. A. (2014). Cancer Chemotherapy Update : Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer. Hospital Pharmacy , 49(5):425–431.
• L R Wiseman, C. M. (1998). Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynecological cancers. Drugs Aging. ,
12(4):305-34.
• Leona A. Holmberg, P. P. (2014). Docetaxel and Carboplatin as Salvage Therapy for First-Relapsed, Platinum-Sensitive, Stage III/IV Advanced Ovarian Cancer. Clinical
Ovarian and Other Gynecologic Cancer , Volume 7, Issues 1–2.
• Madeira Halawa, W. E. (2021). evaluasi pengelolaan obat rusak atau kadaluarsa terhadap sediaan farmasi di salah satu rumah sakit umum swasta kota bandung. Jurnal
Education and development, Vol.9 No.4.
• Muhammad Rafi Akbar, D. M. (2023). Analisis Deskriptif Motivasi Belajar Siswa Melalui Model Belajar Kombinasi Pada Pandemi Covid-19. Jurnal Pendidikan, Sosial dan
Humaniora, Vol.2, No.5.
• S, S. (2023 ). Gambaran Efek Samping obat Sitotoksik pada Pasien Kanker yang Menjalani KemoteraPI di RSUP Fatmawati Jakarta tahun 2023. Jurnal Farmasi Klinik Best
Practice Volume 3 N, Volume 3 No. 1.
• Sudibyo, R. R. (2012). Kajian Peraturan Perundang-undangan Tentang Pemberian Informasi Obat. Jurnal Kefarmasian Indonesia , 2.1. : 20 - 27.
• Tiffany A. Troso-Sandoval, S. M. (2015). Chemotherapy of ovarian cancer in elderly patients. Cancer Biol Med , 12:292-301.
• XUEJIAO LI, Z. L. (2024). Ovarian cancer: Diagnosis and treatment strategies. oncology letters, 28 : 441.
• Yan Zhou, a. W. (2023). Review Article : Efficacy and Safety of Paclitaxel and Carboplatin for Platinum Sensitive Ovarian Cancer: A Systematic Review and Meta-Analysis.
Journal of Clinical Pharmacy and therapeutic